Pharmaceuticals
Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
* Studies conducted by independent labs demonstrate the amubarvimab/romlusevimab combination retains neutralizing activity against COVID-19 Omicron variant * Review of the monoclonal antibody combination therapy is underway by the U.S. Food and Drug Administration (FDA) for Emergency Use Auth...
2022-05-09 19:46
3715
Series A financing round lays foundation for international growth of digital cancer therapeutics Mika
New investors with a successful track record in digital oncology support German Digital Therapeutics (DTx) company Fosanis to broaden patient access of Mika – an app-based DTx platform empowering people affected by cancer. BERLIN, LAUSANNE,Switzerland, BARCELONA,Spain and MUNICH, May 9, 2022 /PR...
2022-05-09 19:35
2710
Takeda Malaysia receives coveted HR accolades by creating an exceptional people experience
Key points: * Takeda Malaysia receives Great Place to Work® award for the first time and Top Employer certification for the sixth consecutive year. * A significant majority of employees surveyed in Malaysia in 2021 Great Place to Work® Trust Index stated that Takeda is a great workplace. * ...
2022-05-09 09:05
2983
Takeda Singapore receives coveted HR accolades by creating an exceptional people experience
Key points: * Takeda Singapore receives Great Place to Work® award for the first time and Top Employer certification for the sixth consecutive year. * A significant majority of employees surveyed in Singapore in 2021 Great Place to Work® Trust Index stated that Takeda is a great workplace. ...
2022-05-09 09:00
2922
InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers
NANJING, China, May 8, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $15 million in Series B+ Fin...
2022-05-09 08:04
2392
ExoCoBio Receives Japanese Patent for Alleviating Dermatitis with Adipose Stem Cell-Derived Exosome
* To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment * To prove the technological feasibility of ExoSCRT™ for the mass-production of the world's best exosomes with high efficacy SEOUL, Korea, May 9, 2022 /PRNewswire/ -- ExoC...
2022-05-09 07:00
5247
Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report
DURHAM, N.C. and BEIJING, May 7, 2022 /PRNewswire/ -- Brii Biosciences Limited
2022-05-07 09:00
6675
Antengene to Participate in Three Upcoming Investor Conferences in May/June
CICC Healthcare Industry Forum 2022: May 9th to 12th BTIG Virtual China Biotech Day: June 1st Citi's 3rd Pan-Asia Regional Investor Conference 2022: June 8th to June 10th SHANGHAI and HONG KONG, May 6, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading inno...
2022-05-06 08:30
3673
Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 5, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX:02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, is pleased to announce the appointment o...
2022-05-06 08:00
2773
Insilico Medicine expands synthetic lethality portfolio with the nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers
NEW YORK, May 6, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-de...
2022-05-06 05:00
3772
Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers
NEW YORK, May 5, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-de...
2022-05-05 23:00
3705
HOYA Vision Care Releases Results of First of its Kind Six-Year MiYOSMART Spectacle Lens Follow-up Clinical Study
Strong evidence shows continued long-term lens effectiveness in slowing myopia progression in children BANGKOK, May 5, 2022 /PRNewswire/ -- HOYA Vision Care, a leader in optical technology innovation, shared the results of asix-year follow-up clinical study on its award winning MiYOSMART spectac...
2022-05-05 22:12
6021
Daewoong Pharmaceutical announced first-quarter 2022 results
- Marked sales of KRW 272.2 billion and operating profit of KRW 26.8 billion - Reported record-high quarterly operating profit, thanks to highly profitable ETC drugs and export growth of Nabota - Expected to see increasing profitability and robust growth due to export expansion of Nabota and the...
2022-05-05 21:00
2743
TIKOMED and IQVIA announce a strategic collaboration for the development of TIKOMED's lead drug platform candidate ILB®
VIKEN, Sweden, May 5, 2022 /PRNewswire/ -- Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative p...
2022-05-05 20:40
1916
I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act
SHANGHAI and GAITHERSBURG, Md., May 5, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provided updates on its status under the Holding Foreign...
2022-05-05 20:00
2209
111, Inc. Provides Updates on its Status Under the Holding Foreign Companies Accountable Act
SHANGHAI, May 5, 2022 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, today announced that onMay 4th, 2022, the Securities and Exchange Commission (the "SEC") provisionally listed the Company as a "Commission-Identified ...
2022-05-05 17:18
2617
Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV
TAIZHOU, China, May 5, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that the Company has recently received the clinical trial approval (the "Clinical Trial Approval") for its recombin...
2022-05-05 11:55
4239
First Patient Dosed in Phase II Renal Cancer Theranostics Study
MELBOURNE, Australia and INDIANAPOLIS, May 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the 'STARLITE 2' Phase II study of the Company's investigational renal cancer therapy, TLX250 (177 Lu-DOTA-girentu...
2022-05-05 05:00
3347
Kintor Pharma Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma
SUZHOU, China, May 4, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing inthe United States of its multi-regional pha...
2022-05-04 20:36
2968
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*
LUGANO, Switzerland, and SINGAPORE, May 4, 2022 /PRNewswire/ -- Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, and Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of innova...
2022-05-04 14:00
2817
Week's Top Stories
Most Reposted
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
[Picked up by 325 media titles]
2026-08-05 11:34
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 296 media titles]
2026-08-04 07:00
Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 295 media titles]
2026-08-06 15:10
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
[Picked up by 292 media titles]
2026-08-04 14:30
Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy
[Picked up by 289 media titles]
2026-08-04 06:00
Most Read
Association of Trade and Commerce Reinforces Commitment to Supporting Singapore Enterprises Through Global Growth at The Entrepreneur Singapore 2026
2026-07-31 21:45
21633
CLASSYS Appoints Former Samsung Electronics Executive Vice President Jun-oh Yoon as CEO to Lead Its Next Stage of Global Growth
2026-07-31 23:12
11228
Oxford International Digital Institute Launches Oxford ELLT Express to Support Time-Sensitive Student Applications
2026-07-31 22:57
10248
